Evidence map›Paper›PMID 41139148›Full record

ArticleProstate cancer and prostatic diseases2026

HLA class I expression shapes the tumor immune microenvironment and influences prognosis in prostate cancer.

Pornlada Likasitwatanakul, Carissa Besonen, Alexander K Tsai, Negar Sadeghipour, Andrew Elliott, Ali T Arafa, Rachel Passow, Lisa Chesner, Martin Felices, Philippa R Kennedy and 7 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Prostate cancer and prostatic diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors.

Pornlada LikasitwatanakulDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0003-3531-3851
Carissa BesonenSchool of Medicine, Creighton University, Omaha, NE, 68178, USA.ORCID http://orcid.org/0009-0008-6586-800X
Alexander K TsaiDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0002-4014-1946
Negar SadeghipourDepartment of Medical Affairs, Caris Life Sciences, Irving, TX, 85040, USA.
Andrew ElliottDepartment of Medical Affairs, Caris Life Sciences, Irving, TX, 85040, USA.
Ali T ArafaMasonic Cancer Center, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.
Rachel PassowDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.
Lisa ChesnerDepartment of Urology, University of California San Francisco, San Francisco, CA, 94115, USA.
Martin FelicesDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.
Philippa R KennedyDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0003-0239-5440
Akash PatnaikSection of Hematology/Oncology, Department of Medicine, University of Chicago, Chicago, IL, 60637, USA.
Vivek NarayanDepartment of Medicine, University of Pennsylvania, Philadelphia, PA, 19104, USA.ORCID http://orcid.org/0000-0002-8205-738X
James HamrickDepartment of Medical Affairs, Caris Life Sciences, Irving, TX, 85040, USA.
Laura A SenaSidney Kimmel Comprehensive Cancer Center, Johns Hopkins University, Baltimore, MD, 21231, USA.ORCID http://orcid.org/0000-0001-6724-9546
Nicholas A ZorkoDepartment of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA.ORCID http://orcid.org/0000-0001-7021-968X
Justin H Hwang *Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA. jhwang@umn.edu.
Emmanuel S Antonarakis *Department of Medicine, University of Minnesota-Twin Cities, Minneapolis, MN, 55455, USA. anton401@umn.edu.ORCID http://orcid.org/0000-0003-0031-9655

Funding

Women's CancerP30CA077598 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Timothy C. Hallstrom · 1998 to 2026
$100.4M
TRAINING GRANT IN MICROBIOLOGY/CANCER RESEARCHT32CA009138 · NCI · UNIVERSITY OF MINNESOTA TWIN CITIES · PI Scott M. Dehm · 1985 to 2026
$11.3M
Dissecting mechanisms of sensitivity to B7-H3 (CD276)-targeted therapeutics in prostate cancer (PC)R37CA288972 · NCI · UNIVERSITY OF MINNESOTA · PI Justin H. Hwang · 2024 to 2026
$1.1M
American Cancer Society (American Cancer Society, Inc.) PF-23-1153194-01-CDPNCI NIH HHS P30 CA077598NCI NIH HHS R37 CA288972NCI NIH HHS T32 CA009138U.S. Department of Defense (United States Department of Defense) W81XWH-22-2-0025U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) R37CA288972
6 · The paper itself

Abstract

backgroundHuman leukocyte antigen (HLA) class I encompasses peptide-binding proteins that regulate T-cell interactions. We examined HLA class I expression in prostate cancers (PC), exploring associations with clinical outcomes, molecular features, and tumor immune microenvironment.

methodsWe analyzed 8040 PC samples from the Caris Life Sciences database, stratifying them into HLA-high (upper quartile) and -low (lower quartile) groups. Genomic and transcriptomic alterations were compared. Immune cell fractions were inferred using quanTIseq, and overall survival (OS) data was obtained from insurance claims. Differences were computed with Cox proportional hazards.

resultsAmong 66 cancer types, PC ranked 3

conclusionsIn PC, elevated HLA class I levels correlate with immune activity, molecular characteristics, and clinical outcomes. We suggest considering HLA expression as a supplementary marker of immune activity in PC, alongside genetic mutations and transcriptomic markers.

Indexed as

Biomarkers, TumorHistocompatibility Antigens Class IProstatic NeoplasmsTumor MicroenvironmentAgedGene Expression Regulation, NeoplasticHumansMaleMiddle AgedPrognosisBiomarkers, TumorHistocompatibility Antigens Class I

Identifiers

PMID41139148
PMCPMC12980528

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.